Use of Dried Plasma Spots for HIV-1 Viral Load Determination and Drug Resistance Genotyping in Mexican Patients

Juan Pablo Rodriguez-Auad,1,2 Othon Rojas-Montes,1 Angelica Maldonado-Rodriguez,1 Ma. Teresa Alvarez-Muñoz,2 Onofre Muñoz,2 Rocio Torres-Ibarra,3 Guillermo Vazquez-Rosales,1 and Rosalia Lira1

1Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, UMAE Hospital de Pediatría, CMN Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Avenida Cuauhtémoc 330, Colonia Doctores, 06720 Mexico City, DF, Mexico
2Department of Pediatric Infectious Diseases, Hospital Infantil de México Federico Gómez, Dr. Marquez 162, Colonia Doctores, 06720 Mexico City, DF, Mexico
3Hospital de Infectología, UMAE Centro Medico Nacional “La Raza”, Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo S/N, Colonia La Raza, 02990 Mexico City, DF, Mexico

Correspondence should be addressed to Rosalia Lira; rolica36@yahoo.com

Received 8 September 2015; Accepted 19 November 2015

Monitoring antiretroviral therapy using measurements of viral load (VL) and the genotyping of resistance mutations is not routinely performed in low- to middle-income countries because of the high costs of the commercial assays that are used. The analysis of dried plasma spot (DPS) samples on filter paper may represent an alternative for resource-limited settings. Therefore, we evaluated the usefulness of analyzing DPS samples to determine VL and identify drug resistance mutations (DRM) in a group of HIV-1 patients. The VL was measured from 22 paired plasma and DPS samples. In these samples, the average VL was 4.7 log_{10} copies/mL in liquid plasma and 4.1 log_{10} copies/mL in DPS, with a correlation coefficient of R = 0.83. A 1.1 kb fragment of HIV pol could be amplified in 14/22 (63.6%) of the DPS samples and the same value was amplified in plasma samples. A collection of ten paired DPS and liquid plasma samples was evaluated for the presence of DRM; an excellent correlation was found in the identification of DRM between the paired samples. All HIV-1 pol sequences that were obtained corresponded to HIV subtype B. The analysis of DPS samples offers an attractive alternative for monitoring ARV therapy in resource-limited settings.

1. Introduction

The prevalence of HIV-1 infection has been increasing all over the world, especially in low- and middle-income countries (LMICs). A 2013 report issued by the Joint United Nations Programme on HIV and Acquired Immune Deficiency Syndrome (UNAIDS) estimates that an average of 35.3 million people (range: 32.2 million–38.8 million) were living with HIV at the end of 2012 [1] and that 5.25 million people in LMICs were receiving antiretroviral (ARV) therapy [2]. Despite the accessibility of ARV therapy in these countries, the widespread monitoring of HIV treatment efficacy by evaluating viral load (VL) levels and analyzing of drug resistance (DR) has been suboptimal [3]. In contrast, in high-income countries (HICs) where the treatment of HIV is more closely monitored the emergence of HIV mutations that confer DR to ARV drugs has increased [4].

In HICs, the monitoring of ARV therapy using VL and genotypic resistance testing is essential to determining cases of treatment failure [5]; the quantification of VL serves as an indicator for whether ARV therapy leads to success or failure in HIV infected patients [6]. To limit the emergence of resistance to ARV drugs, patients undergoing treatment for HIV should ideally undergo periodic virological monitoring, such as VL and genotypic resistance testing, to identify cases in which therapy has failed and to avoid the accumulation of drug resistance mutations (DRM) [7].
The emergence of drug-resistant HIV remains a significant obstacle to the long-term success of therapy; however, it is costly to monitor patients by screening for VL and ARV drug resistance. A portion of this cost stems from the logistics that are involved in sample collection and transport [8]. Because of both the expenses and the logistic challenges that arise during sample collection and transportation from points of care to reference laboratories, VL and genotypic resistance tests remain unavailable to the majority of HIV-infected individuals in resource-limited settings [9].

The use of DPS provides an attractive alternative for monitoring ARV therapy in HIV patients in LMICs [11], as DPS samples can be shipped from distant point-of-care clinics to central laboratories [12], and not only the cost reduction is in the collection and transport process, but also in the sample processing using an in-house assay. Dried blood, plasma, and serum spots (DBS, DPS, and DSS, resp.) have been successfully used to quantify viral RNA and evaluate genotypic drug resistance [5, 7, 13, 14]; however, select limitations and challenges continue to inhibit their practical use. These limitations include the lower limits of detection, the instability of nucleic acids in long-term storage, and the interference of proviral DNA. There is also the potential to overestimate the VL measurement and amplification success of DBS samples [14]. Although the World Health Organization (WHO) accepts the use of DBS for VL monitoring, in the case of evaluating genotypic resistance mutations, there are still several technical and interpretation issues to resolve. In the majority of the research conducted to date, DBS samples have been used to measure VL and perform genotyping; however, the best available sample for these measurements is actual plasma. We have previously reported only a 38.6% amplification success rate using the ViroSeq genotyping assay on DBS samples, which was likely due to either the PCR inhibitors that are present in erythrocytes or to sample storage conditions [15]. In this study, we evaluated the usefulness of analyzing DPS samples to determine viral load (VL) and identify drug resistance mutations in Mexican patients with HIV-1 infection.

2. Materials and Methods

2.1. Study Population. The study protocol was approved by the Ethics Committee and the Institutional Review Boards of the IMSS. Written informed consent was obtained from each participant. A group of 22 adults who were already infected with HIV-1 and receiving ARV therapy were enrolled in our study over the course of February 2009 to March 2010. These patients were receiving healthcare at the La Raza Infectious Diseases Hospital, a tertiary referral center of the IMSS.

2.2. Preparation of Plasma Samples and DPS. An 8 mL blood sample was collected from each of the 22 patients who were infected with HIV. The blood was collected into EDTA-coated sampling tubes. These samples were then centrifuged to isolate the liquid plasma, which was subsequently stored at −70 °C until testing. DPS specimens were made by spotting 50 μL of plasma per circle on filter paper (Schleicher & Schuell 903; Keene, NH, USA), which were then dried for 2h at RT. The DPS samples were individually placed into small plastic bags with a sachet of desiccant (WA Hammond Drierite Co., Ltd., USA) and were stored at −20 °C for an average of one week. One sample (HIV-22) was stored for 910 days at −20 °C.

2.3. Viral Load Measurement. The RNA-HIV-1 VL in plasma and DPS were determined using the Amplicor HIV-1 monitor test, version 1.5 (50 to 750,000 copies/mL; Roche Diagnostics, Indianapolis, IN), according to the manufacturer’s instructions. To measure RNA-HIV VL in DPS samples, a modification in the nucleic acid extraction was used as previously reported [15]. Briefly, two spots per sample were eluted in 100 μL of elution buffer. Because the initial RNA volumes of plasma and DPS were different (500 μL and 100 μL, resp.), we multiplied the VL value obtained from DPS by 5 to normalize the data.

2.4. Nucleic Acid Extraction. RNA was extracted from the DPS samples using a NucliSens HIV-1 QT assay, NASBA Diagnostics procedure (bioMerieux, Inc., Durham, NC). Two whole spots, containing 100 μL of dried plasma (50 μL per spot), were cut with scissors and were transferred to a tube containing 9 mL of NucliSens lysis buffer (Organon Teknika, Durham, NC, USA), following incubation at RT under gentle rotation for 1h. The nucleic acids were then extracted according to the manufacturer’s instructions and resuspended in 100 μL of elution buffer for storage at −70 °C until use. The RNA from the plasma samples was extracted using the QIAamp UltraSens Virus Kit (Qiagen) according to the manufacturer’s instructions.

2.5. PCR Amplification for Genotypic Drug Resistance Testing. We used the HIV-1 genotype assay that was previously reported by Inzaule et al. to validate the use of DPS samples in the genotype resistance assay [16]. A collection of primers that were previously described by Zhou et al. was used to amplify the section of the HIV-1 pol gene that encoded amino acids 6 to 99 of the protease (PR) region and codons 1 to 251 of the reverse transcriptase (RT) region of the HIV-1 genome [9]. Briefly, 10 μL samples of nucleic acid extracts isolated from either plasma or DPS were assessed by one-step RT-PCR using the PRTM-F1 outer primer pair, which is a 1:1 (wt/wt) combination of two forward primers, Fla (positions 2057 to 2085) and F1b (positions 2068 to 2092), RT-R1 (reverse, positions 3370 to 3348), and the SuperScript II one-step RT-PCR system with Platinum Taq high-fidelity polymerase, according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA). For nested PCR, 8 μL of the RT-PCR product was used with the inner forward primer PRT-F2 (positions 2243 to 2266) and reverse RT-R2 (positions 3326 to 3304), lx Phusion HF Buffer, 2 mM MgCl2, 0.4 mM dNTP, and 0.5 U of Phusion High-Fidelity DNA Polymerase (BioLabs) to amplify an amplicon of approximately 1.1 kb.

2.6. Sequencing Drug Resistance Mutations (DRM). The 1.1 kb PCR products obtained from the RT-PCR were purified and directly sequenced using the BigDye Terminator Version 3.1
Cycle Sequencing Kit in an ABI 3100 sequencer (Applied Biosystems, Carlsbad, CA) using PRT-F2 and RT-R2 primers. Confirmation of base calling and sequence editing was conducted using CLC bio 6.0 version software. The presence of DRM in the PR and RT was identified using the Stanford genotyping drug resistance interpretation algorithm (v.4.2.6).

2.7. Phylogenetic Analysis. Phylogenetic analysis was performed using the neighbor-joining method and the reliability of the branching orders was assessed by using the bootstrap approach (1000 replicates) with Mega 6.06 software [10].

2.8. Statistical Analysis. The Pearson coefficient was used to determine the VL association between plasma and DPS samples. Student's t-test was used to compare VLs between paired samples. A p value of <0.05 was considered significant.

3. Results

3.1. The Correlation of HIV-1-RNA VL between Plasma and DPS Samples. The mean VL was 4.7 log_{10} copies/mL (range 2.1 to 6.2) in liquid plasma samples and 4.1 log_{10} copies/mL (range 1.7 to 6.1) in DPS samples; thus, the difference in VL values was 0.6 log_{10} copies/mL, which was not statistically significant (p = 0.26). The data from 22 paired specimens are shown in Table 1. The linear regression analyses of the log-transformed RNA measurements (log_{10} copies/mL) for paired specimens of HIV-1 RNA VL in liquid plasma versus DPS samples (Figure 1) showed a good Pearson correlation (0.83). Only a single sample (HIV-03) produced a difference between the VL values of above 1.0 log_{10}.

3.2. PCR Amplification of the HIV-1 pol Sequence in DPS and Plasma Paired Samples. The average storage time for 21 out of the 22 samples that were assayed was 7.3 days, whereas one DPS sample (HIV-22) was stored for 910 days, just to see the amplification of a sample stored for a long period of time (Table 1). The 1.1 kb fragment of HIV-1 pol was amplified in 63.6% (14/22) of the 22 paired samples. All samples that could be amplified from DPS were also amplified in their paired liquid plasma, with the exception of sample HIV-55. Only one sample (HIV-88) could be amplified from liquid plasma but not from DPS.

3.3. Comparison of DPS and Plasma-Derived Consensus pol Sequences Obtained from Patient Specimens Using an In-House Assay. To assess the reproducibility of the in-house assay compared to a commercial method (ViroSeq), the HIV RNA from sample HIV-27, which was previously genotyped with ViroSeq, was amplified with the in-house method and the resultant sequence was compared against the HIV-1 pol sequence. The phylogenetic analysis showed a high correlation between the sequences (Figure 2).

A total of twenty-two HIV-1 pol sequences were analyzed to determine the percentage of their similarity using the Mega 6.06 program. The mean similarity between HIV pol nucleotide sequences that were obtained from plasma and DPS samples was 98.3%, with a range of 95% to 99%. All sequenced samples corresponded to HIV-1 subtype B.

3.4. Comparison of Drug Resistance Mutations in Paired Plasma versus DPS Samples. A total of ten paired DPS/plasma samples were analyzed, and the presence of DRM and susceptibility to ARV drugs were both determined using the Stanford HIV database. The mutations associated with DR and the genotype interpretation of 20 plasma and DPS-derived PR and RT gene sequences are shown in Table 2. A total of 60% (6/10) of the paired samples contained DRM in the PR and/or RT genes. There was no difference in the DRM found between plasma and DPS samples in seven of the paired samples. Three samples (HIV-13, HIV-20, and HIV-22) indicated some degree of discordance (Table 2). For instance, in one case, the L10F mutation in the PR gene was detected in the sample derived from plasma but was not detected in the DPS counterpart; thus, the interpretation of resistance did not change. In another case, the T215Y mutation in the RT gene was only present in the DPS sample but not in the plasma counterpart; again, there was no change in the interpretation of resistance.

4. Discussion

In recent years, there have been efforts to expand the monitoring of ARV treatment into LMICs, where more than
Table 1: Rate of HIV pol sequences PCR amplification from plasma and DPS paired samples.

| ID    | Time of DPS storage (days) | VL \(^*\) (log \(_{10}\) copies/mL) | PCR amplification | DR genotype** |
|-------|---------------------------|-------------------------------------|-------------------|---------------|
|       |                           | Plasma | DPS | Plasma | DPS | Plasma | DPS |
| HIV-47 | 3                          | 6.2    | 6.1 | +      | +   | +     | +   |
| HIV-03 | 7                          | 6.1    | 4.6 | +      | +   | +     | +   |
| HIV-43 | 7                          | 5.4    | 4.8 | +      | +   | +     | +   |
| HIV-08 | 7                          | 5.3    | 4.7 | +      | +   | +     | +   |
| HIV-86 | 7                          | 5.2    | 4.5 | +      | +   | +     | +   |
| HIV-31 | 7                          | 5.1    | 4.9 | +      | +   | +     | +   |
| HIV-55 | 7                          | 5.0    | 4.7 | -      | +   | +     | -   |
| HIV-64 | 7                          | 5.0    | 4.4 | +      | +   | +     | +   |
| HIV-88 | 12                         | 5.0    | 4.4 | +      | -   | -     | -   |
| HIV-20 | 7                          | 5.0    | 4.5 | +      | +   | +     | +   |
| HIV-13 | 12                         | 4.9    | 4.9 | +      | +   | +     | +   |
| HIV-18 | 7                          | 4.8    | 4.0 | +      | +   | +     | +   |
| HIV-54 | 7                          | 4.7    | 3.8 | -      | -   | -     | -   |
| HIV-89 | 7                          | 4.5    | 3.6 | +      | +   | +     | -   |
| HIV-66 | 7                          | 4.3    | 3.5 | -      | -   | -     | -   |
| HIV-69 | 7                          | 4.3    | 3.7 | -      | -   | -     | -   |
| HIV-62 | 7                          | 4.3    | 3.5 | -      | -   | -     | -   |
| HIV-39 | 7                          | 4.2    | 3.5 | -      | -   | -     | -   |
| HIV-04 | 7                          | 4.9    | 4.0 | +      | +   | +     | +   |
| HIV-02 | 7                          | 3.5    | 3.1 | -      | -   | -     | -   |
| HIV-01 | 7                          | 2.1    | 1.7 | -      | -   | -     | -   |
| HIV-22\(^1\) | 910                  | 4.4    | 4.5 | 14/22  | 14/22 | 14/22  | 13/22|

Average ± SD 4.8 ± 0.9 4.2 ± 0.9 14/22 14/22 14/22 13/22

Rate of PCR amplification and genotyping (%) 63.6 59.1

\( ^* \) VL in DPS and liquid plasma using Amplicor HIV-1 Monitor Test, version 1.5.

\( ^{**} \) Stanford genotyping drug resistance interpretation algorithm (v.4.2.6) (http://sierra2.stanford.edu/sierra/servlet/JSierra). DR: drug resistance genotype.

\( ^1 \) HIV-DPS sample stored for 910 days.

90% of new HIV infections are diagnosed; for example, regions in sub-Saharan Africa account for 70% of all AIDS-related deaths [12]. The high costs of the assays that are used to evaluate VL and drug-resistant genotypes present a hurdle to the successful monitoring of ARV therapy; these costs derive from the logistics that are involved in the transport, storage, and processing of blood samples in reference laboratories. In the majority of LMICs, there are few laboratories with the infrastructure and staff skills needed to analyze these samples and most of them are not located near the clinics where patients are following up; therefore, measurements of VL and/or the evaluation of DRM are not routinely performed. Consequently, the WHO criteria that are used to detect treatment failure are based on clinical and immunological parameters. However, studies have shown that these criteria lack the sufficient sensitivity and specificity that are needed to detect true virological failure, which increases the potential that HIV patients undergoing ARV therapy may accumulate numerous DRM, thereby reducing the effectiveness of therapeutic options [17, 18].

The use of DBS samples has been shown to be a safe, robust, and convenient method for the collection, transport, and storage of the small volumes that are used in the analysis of biomarkers [18]. DBS samples have also been used to measure VL [11, 19–26] and assess drug resistance genotypes [13, 14, 21, 27–29] in HIV-1 patients. The preparation of DBS samples does not require a centrifuge and can therefore be performed by unskilled personnel. However, the use of these samples also presents drawbacks, including the overestimation of VL levels due to the presence of proviral DNA within the blood mononuclear cells of the peripheral blood [14, 23, 30]. Another disadvantage of using DBS samples is the need for an appropriate method of removing PCR inhibitors from erythrocytes [31]. Unlike DBS samples, DPS samples provide the advantage of producing VL measurements that are comparable to that of liquid plasma (the gold standard of such measurements) because the contribution of proviral DNA is eliminated in this context. However, standard genotyping assays use plasma
Figure 2: Phylogenetic tree constructed using sequence data generated from 22 HIV pol region paired plasma (P) and DPS (D) samples. The tree incorporating 1000 nonparametric bootstraps, constructed using sequence data from paired plasma and DPS samples. Phylogenetic tree was produced by the neighbor-joining method and the reliability of the branching orders was assessed by using the bootstrap approach with Mega 6.06 software [10]. One reference sequence representing HIV subtype B was included (HXV2-B subtype). Paired samples (P) or DPS are indicated in the patient ID. Sample HIV-27, which was previously genotyped with ViroSeq (VS), was included and paired with the sequence obtained with the in-house genotyping assay from the plasma sample.

for this purpose, and it is notable that DRM appear earlier in plasma than in proviral DNA [32]. Thus, the sensitivity in detecting early treatment failure would be increased when assaying DPS versus DBS samples [5]. It is important to reach the lowest limit of VL detection when analyzing DBS samples. The WHO criteria indicate that in developing countries a VL of 3.7 log_{10} copies/mL is acceptable because the possibility of disease progression is low in patients with a VL below this value [33].

In this study, we were able to measure samples with a VL of >1.7 log_{10} copies/mL. We found a correlation between the VL of the liquid plasma samples (4.7 log_{10}) and the DPS samples (4.1 log_{10}); this 0.6 log_{10} difference was similar to that observed in other studies, in which differences have been measured within the range of 0.077 log_{10} copies/mL [34] to 0.64 log_{10} copies/mL [20]. Therefore, our results suggest that DPS samples can be used to monitor VL in HIV-1 patients. Although there was a >1 log_{10} difference in the VL of one sample in our collection, this was likely a result of either an error during sample preparation or the degradation of the RNA that was extracted from the DPS.

The stability of nucleic acids on filter paper becomes compromised over time and is also affected by the temperature and humidity at which the samples are stored. Previous studies have shown that samples that are stored for long periods of time are inadequately amplified [35]. However, there is also research that indicates that prolonged periods of storage, ranging from one year [29] to up to 5-6 years,
Table 2: Drug resistance mutations in the protease (PR) and reverse-transcriptase (RT) regions of HIV-1 identified in plasma and DPS paired samples.

| Sample ID | HIV-1 Subtype | HIV-1 Codons | PR | RT | Major drug resistance mutations |
|-----------|---------------|--------------|----|----|---------------------------------|
| HIV-03-P  | B             | 21–99        | 1–259 | 1–249 | RT (RTNI): K219Q, K219Q |
| HIV-03-DPS|               |              |      |    | RT (RTNI): K219Q, K219Q |
| HIV-04-P  | B             | 21–99        | 1–259 | 1–259 | None |
| HIV-04-DPS|               | 3–99         | 1–259 | 1–259 | None |
| HIV-47-P  | B             | 9–99         | 1–251 | 1–251 | None |
| HIV-47-DPS|               | 15–99        | 1–248 | 1–248 | None |
| HIV-08-P  | B             | 4–99         | 1–254 | 1–254 | RT (RTNNI): V179D, V179D |
| HIV-08-DPS|               | 3–99         | 1–249 | 1–249 | RT (RTNNI): V108I, V108I |
| HIV-43-P  | B             | 6–99         | 1–254 | 1–254 | RT (RTNNI): V179D, V179D |
| HIV-43-DPS|               | 36–99        | 1–230 | 1–230 | RT (RTNNI): V179D, V179D |
| HIV-86-P  | B             | 3–99         | 1–254 | 1–254 | RT (RTNNI): V179D, V179D |
| HIV-86-DPS|               | 15–99        | 1–249 | 1–249 | RT (RTNNI): V179D, V179D |
| HIV-31-P  | B             | 3–99         | 1–254 | 1–254 | RT (RTNNI): V179D, V179D |
| HIV-31-DPS|               | 42–99        | 1–239 | 1–239 | RT (RTNNI): V179D, V179D |
| HIV-20-P  | B             | 22–99        | 1–250 | 1–250 | PR (PI): V82A**, V82A**, I50M |
| HIV-20-DPS|               | 16–99        | 1–239 | 1–239 | PR (PI): V82A**, V82A**, I50M |
| HIV-13-P  | B             | 38–99        | 1–254 | 1–254 | PR (PI): M46L**, V82A**, K43T**, A71T*, G73C*RT (RTNNI): M41L, D67N, L74V, M184V, L210W, and K219Q |
| HIV-13-DPS|               | 4–99         | 1–259 | 1–259 | PR (PI): M46L**, V82A**, K43T**, A71T*, G73C*RT (RTNNI): M41L, D67N, L74V, M184V, L210W, and T215Y |
| HIV-22-P  | B             | 1–99         | 1–332 | 1–332 | PR (PI): N88S, L10I*, and M46V |
| HIV-22-DPS|               | 16–99        | 1–254 | 1–254 | PR (PI): N88S, M46V |

RTNNI: nonnucleoside reverse-transcriptase inhibitors; RTNI: nucleoside reverse-transcriptase inhibitors; and PI: protease inhibitors.

**Major drug resistance mutations to PI.
*Minor drug resistance mutations to PI.
P = liquid plasma sample.
DPS = dried plasma spot sample.
1Not present in DPS paired sample; 2 not present in plasma paired sample.

The effectiveness of amplification was 61.9% (13/21) in the group of samples that were stored for an average time of 7 days, demonstrating that DPS samples can be used for the RT-PCR amplification of HIV-RNA. Previous research has shown that the VL is a key determining factor of the effectiveness of amplification in DBS samples; using commercial genotyping methods, effective amplification was achieved in DPS samples with a VL above 15,000 copies/mL (4.1 log10) [37] and in DBS samples with VLs above 6,000 (3.7 log10) [38], 10,000 (4.0 log10) [29], and 14,000 copies/mL (4.1 log10) [15]. In our collection of samples that were stored for 7 days, it was possible to amplify the 1.1 kb fragment in the samples that had a VL above 4000 copies/mL (3.6 log10). It has been previously reported that amplification success is lower when using DPS versus DBS samples. For example, it has been reported that using an in-house RT-PCR assay to amplify a 1023 bp fragment of HIV-1 pol gene was possible in DPS samples with a VL of 338,112 copies/mL (5.5 log10) that were stored for 6 years at −30°C and in DPS samples with a VL of 57,375 copies/mL (4.7 log10) that were stored for 5 years at −70°C. In DBS samples, amplification was possible with even lower VL values: 6,452 copies/mL (3.8 log10) and 19,497 copies/mL (4.2 log10), respectively [36]. It has been reported that the success of RT-PCR amplification is greater when using an in-house assay compared to commercial methods such as ViroSeq.
In conclusion, the data obtained in our study demonstrate the feasibility of using DPS samples as a means of monitoring ARV treatment and disease progression. In an ideal scenario, peripheral laboratories could handle the centrifugation of blood samples and the preparation of DPS samples, which would then be mailed within seven days of their preparation to central laboratories where they could be stored at −20 °C until further tested. The ability to efficiently monitor drug resistance in countries with the highest rates of HIV infection would provide a major public health tool for assessing the prevalence of HIV drug resistance in particular regions of the world and could help set guidelines for ARV treatment if necessary. Future research into standardizing the methodology used to process DPS samples could improve the monitoring of ARV treatment for patients living with HIV infection, especially if this method could be adopted for large-scale use.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by CONACYT-SALUD 2004-01-008. The authors thank HildaValdez-Salazar for technical advice and Miguel A. Caniza, M.D., and Kyle M. Johnson, Ph.D., from the International Outreach Program of St. Jude Children’s Research Hospital, Memphis, TN, USA, for their relevant technical advice. Guillermo Vazquez-Rosales is a recipient of an exclusivity scholarship from Fundación IMSS, Mexico.

References

[1] UNAIDS and WHO, "UNAIDS Report on the Global Aids Epidemic-2013," 2013.
[2] WHO, UNICEF, and UNAIDS, “Towards universal access: scaling up priority HIV/AIDS interventions in the health sector,” Progress Report, 2010.
[3] S. D. Reid, S. J. Fidler, and G. S. Cooke, “Tracking the progress of HIV: the impact of point-of-care tests on antiretroviral therapy,” Clinical Epidemiology, vol. 5, no. 1, pp. 387–396, 2013.
[4] J. M. Raboud, M. R. Loutfy, D. Su et al., “Regional differences in rates of HIV-1 viral load monitoring in Canada: insights and implications for antiretroviral care in high income countries,” BMC Infectious Diseases, vol. 10, article 40, 2010.
[5] R. L. Hamers, P. W. Smit, W. Stevens, R. Schuurman, and T. F. Rinke de Wit, “Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review,” Antiviral Therapy, vol. 14, no. 5, pp. 619–629, 2009.
[6] S. Wang, F. Xu, and U. Demirci, “Advances in developing HIV-1 viral load assays for resource-limited settings,” Biotechnology Advances, vol. 28, no. 6, pp. 770–781, 2010.
[7] M. Monleau, A. F. Aghokeng, S. Eymard-Duvernay et al., “Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia,” Journal of Clinical Microbiology, vol. 52, no. 2, pp. 578–586, 2014.
[8] J. Gerlach, M. Sequeira, V. Alvarado et al., "Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting," *Journal of the International AIDS Society*, vol. 13, no. 1, article 43, 2010.

[9] Z. Zhou, N. Wagar, J. R. DeVos et al., "Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings," *PLoS ONE*, vol. 6, no. 11, Article ID e28184, 2011.

[10] K. Tamura, G. Stecher, D. Peterson, A. Filipski, and S. Kumar, "MEGA6: molecular evolutionary genetics analysis version 6.0," *Molecular Biology and Evolution*, vol. 30, no. 12, pp. 2725–2729, 2013.

[11] M. Andreotti, M. Pirillo, G. Guidotti et al., "Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay," *Journal of Clinical Virology*, vol. 47, no. 1, pp. 4–7, 2010.

[12] UNAIDS and WHO, "UNAIDS Report on the Global AIDS Epidemic 2012," 2012.

[13] J. G. García-Lerma, A. McNulty, C. Jennings, D. Huang, W. Heneine, and J. W. Bremer, "Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37°C and high humidity," *Journal of Antimicrobial Chemotherapy*, vol. 64, no. 1, pp. 33–36, 2009.

[14] M. Monleau, C. Butel, E. Delaporte, F. Boillot, and M. Peeters, "Correlation between HIV-1 RNA quantification and PCR amplification for drug resistance genotyping," *Journal of Antimicrobial Chemotherapy*, vol. 65, no. 8, Article ID dks205, pp. 1562–1566, 2010.

[15] R. Lira, H. Valdez-Salazar, G. Vazquez-Rosales et al., "Genotypic testing for HIV-1 drug resistance using dried blood samples," *Archives of Virology*, vol. 155, no. 7, pp. 1117–1215, 2010.

[16] S. Inzaule, C. Yang, A. Kasembeli et al., "Field evaluation of a broadly sensitive HIV-1 In-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country," *Journal of Clinical Microbiology*, vol. 51, no. 2, pp. 529–539, 2013.

[17] J. J. G. van Oosterhout, L. Brown, R. Weigel et al., "Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria," *Tropical Medicine and International Health*, vol. 14, no. 8, pp. 856–861, 2009.

[18] P. Mee, K. L. Fielding, S. Charalambous, G. J. Churchyard, and A. D. Grant, "Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa," *AIDS*, vol. 22, no. 15, pp. 1971–1977, 2008.

[19] M. T. Álvarez-Muñoz, S. Zaragoza-Rodriguez, O. Rojas-Montes et al., "High correlation of human immunodeficiency virus type-1 viral load measured in dried-blood sample and in plasma under different storage conditions," *Archives of Medical Research*, vol. 36, no. 4, pp. 382–386, 2005.

[20] B. Amellal, C. Kalama, and V. Calvez, "Evaluation of the use of dried spots and of different storage conditions of plasma for HIV-1 RNA quantification," *HIV Medicine*, vol. 8, no. 6, pp. 396–400, 2007.

[21] D. Brambilla, C. Jennings, G. Aldrovandi et al., "Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability," *Journal of Clinical Microbiology*, vol. 41, no. 5, pp. 1888–1893, 2003.

[22] C. Garredo, N. Zahnenero, A. Corral, M. Arredondo, V. Soriano, and C. de Mendoza, "Correlation between human immunodeficiency virus type I (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests," *Journal of Clinical Microbiology*, vol. 47, no. 4, pp. 1031–1036, 2009.

[23] A. Johannessen, M. Trosseid, and A. Calmy, "Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings," *Journal of Antimicrobial Chemotherapy*, vol. 64, no. 6, Article ID dks353, pp. 1126–1129, 2009.

[24] A. Johannessen, "Dried blood spots in HIV monitoring: applications in resource-limited settings," *Bioanalysis*, vol. 2, no. 11, pp. 1893–1908, 2010.

[25] A. D. Mbida, S. Sosso, P. Flori et al., "Measure of viral load by using the Abbott Real-Time HIV-1 assay on dried blood and plasma spot specimens collected in 2 rural dispensaries in Cameroon," *Journal of Acquired Immune Deficiency Syndromes*, vol. 52, no. 1, pp. 9–16, 2009.

[26] S. Reigadas, M. H. Schrive, V. Aurillac-Lavignolle, and H. J. Fleury, "Quantitation of HIV-1 RNA in dried blood and plasma spots," *Journal of Virological Methods*, vol. 161, no. 1, pp. 177–180, 2009.

[27] K. Steegen, S. Luchters, E. Demecheler et al., "Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots," *Journal of Clinical Microbiology*, vol. 45, no. 10, pp. 3342–3351, 2007.

[28] C. Yang, A. McNulty, K. Diallo et al., "Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance," *Journal of Clinical Microbiology*, vol. 48, no. 9, pp. 3158–3164, 2010.

[29] A. S. Youngpairo, J. Mascirot, C. Garredo, N. Zahnenero, C. de Mendoza, and J. G. García-Lerma, "HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4°C," *Journal of Antimicrobial Chemotherapy*, vol. 61, no. 6, pp. 1217–1220, 2008.

[30] A. Johannessen, C. Garredo, N. Zahnenero et al., "Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania," *Clinical Infectious Diseases*, vol. 49, no. 6, pp. 976–981, 2009.

[31] A. Akane, K. Matsubara, H. Nakamura, S. Takahashi, and K. Kimura, "Identification of the heme compound copurified with deoxyribonucleic acid (DNA) from bloodstains, a major inhibitor of polymerase chain reaction (PCR) amplification," *Journal of Forensic Sciences*, vol. 49, no. 6, pp. 362–372, 1994.

[32] X. Bi, H. Gatanaga, S. Ida et al., "Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year," *Journal of Acquired Immune Deficiency Syndromes*, vol. 34, no. 1, pp. 1–6, 2003.

[33] WHO, *Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents*, World Health Organization, Geneva, Switzerland, 2009.

[34] S. Cassol, M. J. Gill, R. Pilon et al., "Quantification of human immunodeficiency virus type 1 RNA from dried plasma spots collected on filter paper," *Journal of Clinical Microbiology*, vol. 35, no. 11, pp. 2795–2801, 1997.

[35] A. C. Hearps, C. E. Ryan, L. M. Morris, M. M. Plate, V. Greengrass, and S. M. Crowe, "Stability of dried blood spots for..."
HIV-1 drug resistance analysis,” *Current HIV Research*, vol. 8, no. 2, pp. 134–140, 2010.

[36] A. McNulty, C. Jennings, D. Bennett et al., “Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing,” *Journal of Clinical Microbiology*, vol. 45, no. 2, pp. 517–521, 2007.

[37] R. Dachraoui, A. Depatureaux, M. Chakroun et al., “Monitoring of HIV-1 resistance in Tunisia (North Africa) with a dried plasma spot strategy,” *Journal of Acquired Immune Deficiency Syndromes*, vol. 47, no. 4, pp. 522–525, 2008.

[38] R. Hallack, L. E. Doherty, J. A. Wethers, and M. M. Parker, “Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay,” *Journal of Clinical Virology*, vol. 41, no. 4, pp. 283–287, 2008.

[39] S. Masciotra, C. Garrido, A. S. Youngpairoj et al., “High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients,” *AIDS*, vol. 21, no. 18, pp. 2503–2511, 2007.

[40] S. Bertagnolio, L. Soto-Ramirez, R. Pilon et al., “HIV-1 drug resistance surveillance using dried whole blood spots,” *Antiviral Therapy*, vol. 12, no. 1, pp. 107–113, 2007.